Efforts to develop effective therapies for MYC-amplified Group 3 medulloblastoma (G3-MB) are hindered by an incomplete understanding of how MYC expression is controlled in these tumors. MYC, an oncogene, has long been considered “undruggable,” because it lacks clear pockets for drugs to bind and inhibit its activity. Scientists at St. Jude Children’s Research Hospital have now revealed that these tumors amplify MYC through extrachromosomal DNA (ecDNA) and identified a key enhancer located within tumor ecDNA that regulates its expression. The work is published in Cancer Research.
This article was originally published on MedicalXpress.com
